Omni stock

Private-market facts for current and former Omni employees researching their stock.

Latest Round
Series B
Valuation
Not publicly disclosed
Founded
2021
Headquarters
San Francisco, CA
Founders
Colin Zima, Chris Lambert, Jamie Davidson
Status
private

Talk to a Omni stock specialist

Get personalized guidance on your Omni shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Overview

Omni is a business intelligence platform that combines a shared data modeling layer with a modern SQL IDE and visualization tools for analytics teams.

Omni outlook

Equity outlook95% data confidence
1x
Base scenario
3x
Upside scenario

For employees evaluating Omni equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 3x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.

These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.

Illustrative model · v1.0.0 · Not investment advice

Selling Omni shares

Why shareholders consider selling

Shareholders in Omni may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Omni does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.

Can you sell Omni stock?

Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Data & Analytics sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Omni shares would be outlined in the holder's equity agreement or the company's governing documents.

What affects the value of Omni shares?

The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Data & Analytics market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round can help frame expectations, though they do not guarantee a transaction price.

What should holders check before selling

  • The type of security held (common shares, preferred, options, RSUs)
  • Whether the equity is fully vested and, for options, whether it has been exercised
  • Any transfer restrictions, lock-up provisions, or company approval requirements
  • Estimated net proceeds after applicable taxes and transaction fees
  • Whether partial liquidity — selling a portion rather than the full position — may be a better fit

Tools for Omni shareholders

Exploring equity in Omni often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.

Latest funding round

Omni most recently raised a Series B round . Total funding raised to date is approximately $69M.

Founders & company background

Omni was founded in 2021 by Colin Zima, Chris Lambert, Jamie Davidson and is headquartered in San Francisco, CA.

Industry

Similar private companies

Latest Omni news

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) A
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year’s ASCRS Annual Meeting held in Washington, DC.
The Manila TimesApr 1, 2026
Introduction to Omni Bridgeway and Analyst Data Pack
SYDNEY, March 25, 2026 (GLOBE NEWSWIRE) -- Omni Bridgeway has today released its Introduction to Omni Bridgeway and Analyst Data Pack, providing analysts and investors enhanced transparency into the Group’s business model, portfolio construction, and long-term value creation.
The Manila TimesMar 26, 2026
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will introduce its next-generation KRAS pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. These two non-covalent pan-KRAS inhibitors leverage a differentiated chemical scaffold to address limitations of contemporary molecules - achieving sub-nanomolar potency and a prolonged off-rate, combined with oral bioavailability. In addition, the company will present new preclinical data supporting the continued advancement of its clinical programs BH-30643, a first-in-class, mutant-selective, macrocyclic OMNI-EGFRTM inhibitor, and BH-30236, an oral CLK inhibitor for hematologic malignancies. The AACR Annual Meeting 2026 will be held April 17-22, 2026, in San Diego.
The Manila TimesMar 17, 2026

Talk to a Omni stock specialist

Get personalized guidance on your Omni shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Frequently asked questions

Is Omni still a private company?
Yes, Omni is currently a private company.
What is Omni's latest funding round?
Omni's most recent known round is Series B.
What is Omni's valuation?
Omni's valuation has not been publicly disclosed.
Who are the investors in Omni?
Investor information is not currently available.
Can I sell my Omni stock?
Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Omni stock can help you evaluate your options.

Related pages

Last verified: 2026-04-13 · Omni data compiled from funding disclosures, corporate filings, and public records.

Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.